Explore the 2026 Audience Breakdown
The 5th In Vivo Cell Engineering & Gene Editing Summit will gather 50+ cell and gene therapy decision-makers in Boston this July. Across 3 days, the community will explore advancing targeted in vivo delivery, early clinical validation, and global development strategy. This is the perfect opportunity to benchmark your current in vivo pipelines or explore how in vivo approaches can accelerate your therapeutic pipeline.
Attendee Profile Overview
This year's meeting is set to be the largest and most influential meeting to date. With 40+ organizations and counting set to attend, this is a must-attend meeting for anyone actively working in in vivo cell and gene therapies or exploring how in vivo approaches can be applied to their pipelines.
Companies in Attendance
This year, companies already confirmed to attend include:
- AstraZeneca
- BioNTech
- Bristol Myers Squibb
- CREATE Medicines
- Dispatch Bio
- FUJIFILM Irvine Scientific
- Johnson & Johnson
- Legend Biotech
- Mirai Bio
- Moderna
- Nkarta
- OneChain Immunotherapeutics
- Regeneron Pharmaceuticals
- The Scripps Research Institute
- Tr1x Therapeutics
Explore the Full Program
View the detailed agenda, featured speakers, session highlights, and networking opportunities shaping the fastest‑growing frontier in cell and gene therapy.
Secure Your Place
Join the only meeting dedicated to accelerating in vivo cell engineering and gene editing. Connect with global leaders, access exclusive clinical insights for first-in-human trials, and strengthen your development and delivery strategies.
Showcase Your Capabilities
Position your organization in front of senior R&D and CMC decision-makers at the forefront of this growing field. Attendees are seeking CDMOs, CROs, and vector design expertise to scale their in vivo programs.